Physician profile
Muhammad Shamim
NPI 1326085796
$1,827.23
in general payments reported to CMS, 2019-2025
11 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $53.53 · 2021: $68.69 · 2022: $187 · 2023: $282 · 2024: $456 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.22 |
| Education | $184.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $335.43 | 2024-2025 | Tremfya |
| Amgen INC. | $284.47 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Radius Health, INC. | $269.85 | 2019-2024 | Tymlos |
| Boston Scientific Corporation | $178.22 | 2023 | Embold Fibered |
| Glaxosmithkline, LLC. | $167.16 | 2023-2025 | Benlysta |
| Ucb, INC. | $162.60 | 2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $142.90 | 2020-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $119.27 | 2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $96.43 | 2023-2025 | Saphnelo, Fasenra |
| Lilly USA, LLC | $57.36 | 2021-2024 | Zepbound, Mounjaro |
| Pfizer INC. | $13.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shamim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.